Trillium Therapeutics Inc. (NASDAQ:TRIL) saw a downside of -0.84% to close Tuesday at $17.76 after subtracting -$0.15 on the day. The 5-day average trading volume is 1,352,580 shares of the company’s common stock. It has gained $17.93 in the past week. An average of 1,434,055 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,338,388.
TRIL’s 1-month performance is 3.26% or $0.47 on its low of $17.20 reached on 09/13/21. The company’s shares have touched a 52-week low of $5.80 and high of $20.96, with the stock’s rally to the 52-week high happening on 10/08/21. YTD, TRIL has achieved 20.73% or $3.05. However, the current price is down -15.27%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Jul 07, 98 days have gone by since the last insider trading activity for Trillium Therapeutics Inc. (TRIL). Uger Robert (Chief Scientific Officer) most recently sold 3,646 shares at $9.00 per share on Jul 07. This transaction cost the insider $32,814. Chief Scientific Officer, Uger Robert, sold 3,646 shares at a price of $8.27 on Jun 07. Then, on May 12, President and CEO Skvarka Jan sold 23,802 shares at a price of $9.24 per share. This transaction amounted to $219,880.
Trillium Therapeutics Inc. (TRIL) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector. The company’s PE ratio for the last five years has touched a high of 40.82 and a low of 9.452. TRIL stock has a beta of 1.98. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 15891.60 while the price-to-book (PB) in the most recent quarter is 6.02.
Trillium Therapeutics Inc.’s quick ratio for the period ended June 29 was 19.80, with the current ratio over the same period at 19.80 meaning that TRIL stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is -32678.38%. The firm’s gross profit as reported stood at $61.6 million against revenue of $0.15 million.
For the quarterly period ending June 29 this year, Trillium Therapeutics Inc.’s cash and short-term investments amounted to $94.7 million against total debt of $0.73 million. Analysts expected TRIL to announce -$0.14 per share in earnings in its latest quarter, but it posted -$0.18, representing a -28.60% surprise. EBITDA for the quarter stood at more than -$18.61 million. TRIL stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 14.12 million, with total debt at $0.73 million. Shareholders hold equity totaling $104.81 million
Let’s look briefly at Trillium Therapeutics Inc. (TRIL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 61.65% to suggest the stock is trending Neutral, with historical volatility in this time period at 13.16%.
The stock’s 5-day moving average is $17.78, reflecting a +0.11% or $0.02 change from its current price. TRIL is currently trading +2.30% above its 20-day SMA, +111.18% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +176.64% and +36.41% respectively.
Stochastic %K and %D was 80.32% and 82.82% and the average true range (ATR) pointed at 0.23. The RSI (14) points at 69.94%, while the 14-day stochastic is at 69.09% with the period’s ATR at 0.28. The stock’s 9-day MACD Oscillator is pointing at 0.09 and 0.11 on the 14-day charts.
In the most recent analyst report for Trillium Therapeutics Inc. (NASDAQ: TRIL), The Benchmark Company launched coverage with a Buy rating. Analysts offering their rating for TRIL stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate TRIL as a “sell,”, while 5 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is TRIL’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $18.50 and a high of $18.50, with their median price target at $18.50. Looking at these predictions, the average price target given by analysts is for Trillium Therapeutics Inc. (TRIL) stock is $18.50.